Casirivimab/imdevimab vs placebo: Grades 3 and 4 adverse events
- Population
- SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
- Intervention
- Casirivimab/imdevimab
- Comparison
- placebo
- Outcome
- Grades 3 and 4 adverse events
It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Casirivimab/imdevimab vs placebo Adverse events: grade 3 to 4 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty). SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane Headline outcomes only | RR 0.44 [0.1, 1.95] | 1 study · 969 participants | Very low |
Casirivimab/imdevimab vs placebo Adverse events: grade 3 to 4 until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 Casirivimab/imdevimab showed no clear difference in adverse events: grade 3 to 4 until data cut‐offb compared with placebo (low certainty). SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane Headline outcomes only | RR 0.5 [0.24, 1.02] | 1 study · 2617 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Casirivimab/imdevimab vs placebo · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) · 1 review
- Casirivimab/imdevimab vs usual care · hospitalised individuals with COVID‐19 (moderate to severe disease) · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.